FilingsTodayHigh Tech Pharm
At a glance
High Tech Pharm filed 28 disclosures in the last 12 months, including 6 insider and 3 5% holder. The most recent key filing was on Aug 12.
Revenue for 2025 was ₩70.2B, down 9.5% on 2024. Operating margin was 18.3% against 20.1% a year earlier. Debt was 10% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩37.5B and operating profit of ₩5.2B.
The 2025 annual report lists 130 employees with an average tenure of 5.7 years and average pay of ₩59.1M, #1019 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩122.9M each on average. It paid ₩150 per common share in cash dividends, against ₩100 a year earlier (+50%). ACS Dobfar s.p.a and related parties held 45.17% at year end.
From the 2025 annual report
Staff: 130 (113 men, 17 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩7.8B. Directors and auditors: 6, paid ₩737.7M in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩150 | ₩100 | ₩100 |
| Payout ratio | 13.9% | 7.8% | 8.8% |
| Yield (as filed) | 1.20% | 0.70% | 1.10% |
| Total cash dividends | ₩1.6B | ₩1.1B | ₩709M |
Largest shareholder
ACS Dobfar s.p.a holds 39.57%; with 4 related parties the group holds 45.17% of common shares at year end (from 45.15% at the start of the year).
Auditor: 삼일회계법인 · opinion: Unqualified.
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.